A5084008425- Pregnancy and preeclampsia studies
- Birth, Development, and Health
- Maternal and fetal healthcare
- Gestational Diabetes Research and Management
- Pregnancy and Medication Impact
- Cardiovascular Issues in Pregnancy
- Fetal and Pediatric Neurological Disorders
- COVID-19 Impact on Reproduction
- Prenatal Screening and Diagnostics
- Animal health and immunology
- Reproductive System and Pregnancy
- Agriculture and Farm Safety
- Assisted Reproductive Technology and Twin Pregnancy
- Reproductive Physiology in Livestock
- Genomic variations and chromosomal abnormalities
- Renal and related cancers
- COVID-19 and healthcare impacts
Hospital Universitari Joan XXIII de Tarragona
2020-2025
Consorci Sanitari de Terrassa
2023
Hospital Universitari de Girona Doctor Josep Trueta
2023
Mútua Terrassa
2023
University Hospital Mútua de Terrassa
2023
Universitat Autònoma de Barcelona
2023
Hospital Universitari Germans Trias i Pujol
2023
Universitat Rovira i Virgili
2022
University of Maryland, College Park
1981
Aspirin reduces the incidence of preterm preeclampsia by 62% in pregnant individuals at high risk preeclampsia. However, aspirin might be associated with an increased peripartum bleeding, which could mitigated discontinuing before term (37 weeks gestation) and accurate selection higher first trimester pregnancy.To determine whether discontinuation normal soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1:PlGF) ratio between 24 28 gestation was noninferior continuation...
This study aims to evaluate the safety of discontinuing aspirin treatment at 24-28 weeks in women high risk after first-trimester combined screening for preeclampsia (PE) and normal placental growth factor (PlGF) levels gestation.
Abstract Objective To assess whether aspirin treatment can be discontinued in pregnancies with normal uterine artery pulsatility index (≤90th percentile) at 24–28 weeks. Design Post‐hoc analysis of a clinical trial. Setting Nine maternity hospitals Spain. Population or Sample Pregnant individuals high risk pre‐eclampsia 11–13 weeks and Doppler Methods All participants received daily dose 150 mg. Participants were randomly assigned, 1:1 ratio, either to continue until 36 (control group)...
The association between preeclampsia and coronavirus disease 2019 (COVID-19) is under study. Previous publications have hypothesized the existence of shared risk factors for both conditions or a deficient trophoblastic invasion as possible explanations this association. primary aim study was to examine baseline measured in first-trimester combined screening pregnant women with COVID-19 compared general population. A secondary compare among patients mild severe COVID-19.This an observational...
Abstract Chromosomal microarray analysis (CMA) has now replaced karyotyping in the of prenatal cases with a fetal structural anomaly, whereas those pregnancies undergoing invasive diagnosis normal ultrasound, conventional is still performed. The aims this study were to establish diagnostic yield CMA diagnosis, and provide new data that might contribute reconsider current practices. We reviewed 2905 samples rapid aneuploidy detection test referred for evaluation by testing. Our revealed...
The aim of the study was to assess diagnostic yield 2 different next-generation sequencing (NGS) approaches: gene panel and "solo" clinical exome (solo-CES), in fetuses with structural anomalies normal chromosomal microarray analysis (CMA), absence a known familial mutation.Gene panels encompassing from 140 genes, were applied mainly persistent nuchal fold/fetal hydrops large hyperechogenic kidneys. Solo-CES, which entails fetus alone only interpreting Online Mendelian Inheritance Man...
Fetal smallness affects 10% of pregnancies. Small fetuses are at a higher risk adverse outcomes. Their management using estimated fetal weight and feto-maternal Doppler has high sensitivity for outcomes; however, more than 60% electively delivered 37 to 38 weeks. On the other hand, classification angiogenic factors seems have lower false-positive rate. Here, we present protocol Growth Restriction Term Managed by Angiogenic Factors Versus Feto-Maternal (GRAFD) trial, which compares use manage...
ABSTRACT Preeclampsia affects up to 4% of pregnancies and is marked by the development hypertension proteinuria after 20 weeks gestation. Complications associated with disorder include preterm birth, fetal growth restriction, placental abruption, HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome, seizures, other end organ damage. Aspirin has been shown reduce incidence preeclampsia 62%. However, it can also lead peripartum bleeding. Screening for in first trimester (11 13...
Objective: To examine baseline risk factors measured in the first-trimester screening for preeclampsia (PE) pregnant women with COVID-19 versus general population. compare among patients mild and severe COVID-19. Design: Observational retrospective study. Setting: Six maternities Catalonia. Population: Study were 231 undergoing PE positive SARS-CoV-2. Reference cohort 13,033 from 6 maternities. Methods: Recording of maternal history, mean arterial blood pressure (MAP), uterine artery...
<sec> <title>BACKGROUND</title> Fetal smallness affects 10% of pregnancies. These fetuses are at a higher risk adverse outcomes. Their management using estimated fetal weight (EFW) and feto-maternal Doppler has high sensitivity for outcomes; however, more than 60% electively delivered 37-38 weeks. On the other hand, classification angiogenic factors (AF) seems to have lower false positive rate. Here we present protocol GRAFD trial, which compares small term AF or Doppler. </sec>...